In this 2016 study by Duan et al., Peptidylarginine deiminase IV (PAD4) overexpression was found to halt EMT progression and suppress gefitinib resistance in NSCLC cells [55]. The gene discussed is PADI4; the disease is non-small cell lung carcinoma.